SRAX INC (SRAX) Fundamental Analysis & Valuation

NASDAQ:SRAX • US78472M1062

Current stock price

0.6 USD
-0.98 (-62.03%)
At close:
0.62 USD
+0.02 (+3.33%)
After Hours:

This SRAX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. SRAX Profitability Analysis

1.1 Basic Checks

  • In the past year SRAX has reported negative net income.
  • In the past year SRAX has reported a negative cash flow from operations.
SRAX Yearly Net Income VS EBIT VS OCF VS FCFSRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 -10M -20M -30M

1.2 Ratios

  • SRAX has negative profitability rations, so we won't be analyzing them here.
  • With a decent Return On Invested Capital value of 0.04%, SRAX is doing good in the industry, outperforming 73.06% of the companies in the same industry.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC 0.04%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRAX Yearly ROA, ROE, ROICSRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 50 -50 -100 -150 -200

1.3 Margins

  • The Operating Margin of SRAX (0.05%) is better than 73.06% of its industry peers.
  • With a decent Gross Margin value of 73.34%, SRAX is doing good in the industry, outperforming 70.03% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SRAX has grown nicely.
Industry RankSector Rank
OM 0.05%
PM (TTM) N/A
GM 73.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.58%
GM growth 5Y16.6%
SRAX Yearly Profit, Operating, Gross MarginsSRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. SRAX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SRAX is destroying value.
  • The number of shares outstanding for SRAX has been increased compared to 1 year ago.
  • The debt/assets ratio for SRAX has been reduced compared to a year ago.
SRAX Yearly Shares OutstandingSRAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
SRAX Yearly Total Debt VS Total AssetsSRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

2.2 Solvency

  • SRAX has an Altman-Z score of 0.23. This is a bad value and indicates that SRAX is not financially healthy and even has some risk of bankruptcy.
  • SRAX has a Altman-Z score of 0.23. This is in the lower half of the industry: SRAX underperforms 67.00% of its industry peers.
  • There is no outstanding debt for SRAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.23
ROIC/WACC0
WACC10.1%
SRAX Yearly LT Debt VS Equity VS FCFSRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 1.13 indicates that SRAX should not have too much problems paying its short term obligations.
  • SRAX has a worse Current ratio (1.13) than 71.72% of its industry peers.
  • SRAX has a Quick Ratio of 1.13. This is a normal value and indicates that SRAX is financially healthy and should not expect problems in meeting its short term obligations.
  • SRAX's Quick ratio of 1.13 is on the low side compared to the rest of the industry. SRAX is outperformed by 71.04% of its industry peers.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.13
SRAX Yearly Current Assets VS Current LiabilitesSRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. SRAX Growth Analysis

3.1 Past

  • SRAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.18%, which is quite impressive.
  • Looking at the last year, SRAX shows a very strong growth in Revenue. The Revenue has grown by 109.34%.
  • The Revenue has been decreasing by -5.67% on average over the past years.
EPS 1Y (TTM)42.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%123.2%
Revenue 1Y (TTM)109.34%
Revenue growth 3Y39.3%
Revenue growth 5Y-5.67%
Sales Q2Q%37.85%

3.2 Future

  • SRAX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 50.52% yearly.
  • The Revenue is expected to decrease by -5.17% on average over the next years.
EPS Next Y124.58%
EPS Next 2Y50.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-7.07%
Revenue Next 2Y-5.17%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SRAX Yearly Revenue VS EstimatesSRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
SRAX Yearly EPS VS EstimatesSRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. SRAX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SRAX. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 1.95 indicates a rather cheap valuation of SRAX.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SRAX indicates a rather cheap valuation: SRAX is cheaper than 100.00% of the companies listed in the same industry.
  • SRAX is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.36, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 1.95
SRAX Price Earnings VS Forward Price EarningsSRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -65.27
SRAX Per share dataSRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • SRAX's earnings are expected to grow with 50.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.52%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SRAX Dividend Analysis

5.1 Amount

  • No dividends for SRAX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SRAX Fundamentals: All Metrics, Ratios and Statistics

SRAX INC

NASDAQ:SRAX (3/8/2023, 8:07:58 PM)

After market: 0.62 +0.02 (+3.33%)

0.6

-0.98 (-62.03%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Industry Strength8.7
Industry Growth62.73
Earnings (Last)02-02
Earnings (Next)04-03
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners9.92%
Ins Owner Change0%
Market Cap15.79M
Revenue(TTM)28.76M
Net Income(TTM)-19.94M
Analysts84.44
Price Target6.73 (1021.67%)
Short Float %0.63%
Short Ratio0.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-107.64%
Min EPS beat(2)-107.64%
Max EPS beat(2)-107.64%
EPS beat(4)0
Avg EPS beat(4)-1488.54%
Min EPS beat(4)-3627.65%
Max EPS beat(4)-107.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-35.89%
Min Revenue beat(2)-49.18%
Max Revenue beat(2)-22.6%
Revenue beat(4)1
Avg Revenue beat(4)-15.97%
Min Revenue beat(4)-49.18%
Max Revenue beat(4)9.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-24.72%
EPS NQ rev (1m)47.14%
EPS NQ rev (3m)-130.83%
EPS NY rev (1m)-20.14%
EPS NY rev (3m)-20.14%
Revenue NQ rev (1m)-19.15%
Revenue NQ rev (3m)-19.15%
Revenue NY rev (1m)-40.35%
Revenue NY rev (3m)-40.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.95
P/S 0.55
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 2.97
EV/EBITDA -65.27
EPS(TTM)-1.16
EYN/A
EPS(NY)0.31
Fwd EY51.34%
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS1.09
BVpS0.94
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC 0.04%
ROICexc N/A
ROICexgc N/A
OM 0.05%
PM (TTM) N/A
GM 73.34%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.58%
GM growth 5Y16.6%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 1.6
Cap/Depr 127.87%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 1.13
Altman-Z 0.23
F-Score4
WACC10.1%
ROIC/WACC0
Cap/Depr(3y)101.84%
Cap/Depr(5y)118.99%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%123.2%
EPS Next Y124.58%
EPS Next 2Y50.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)109.34%
Revenue growth 3Y39.3%
Revenue growth 5Y-5.67%
Sales Q2Q%37.85%
Revenue Next Year-7.07%
Revenue Next 2Y-5.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y100.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year322.13%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.54%
OCF growth 3YN/A
OCF growth 5YN/A

SRAX INC / SRAX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SRAX INC (SRAX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRAX.


Can you provide the valuation status for SRAX INC?

ChartMill assigns a valuation rating of 7 / 10 to SRAX INC (SRAX). This can be considered as Undervalued.


How profitable is SRAX INC (SRAX) stock?

SRAX INC (SRAX) has a profitability rating of 1 / 10.


What is the financial health of SRAX INC (SRAX) stock?

The financial health rating of SRAX INC (SRAX) is 2 / 10.


Can you provide the expected EPS growth for SRAX stock?

The Earnings per Share (EPS) of SRAX INC (SRAX) is expected to grow by 124.58% in the next year.